Q BioMed Inc (OTC US:QBIO:) CEO Denis Corin tells Proactive Investors the commercial-stage biotechnology acceleration company is waiting for the US Food and Drug Administration to sign off on a new manufacturing facility to produce Strontium Chloride Sr89 injection.
Corin says he is hopeful the FDA will approve the facility in the next 30 days and is excited to bring the non-opioid pain analgesic to the market.
Meet360 Blockchain Inc at our event,New York, 18 April 2018.Register here >>